Neuroblastoma

Neuroblastoma arises from immature sympathetic nerve cells, often in the adrenal region or beside the spine. It mainly affects young children and differs from a brain tumor despite its name. Abdominal swelling, bone pain, a limp, unusual bruising around the eyes or a neck/chest mass can lead to investigation; symptoms alone do not establish the diagnosis.

A tumor near the spine can compress the spinal cord. New limb weakness, walking difficulty or bladder/bowel dysfunction needs urgent assessment. Rapid abdominal enlargement with breathing difficulty in an infant also needs prompt care. Most families have no identifiable inherited cause; family history or multiple primary tumors can prompt genetic assessment.

The work-up combines tumor imaging, pathology, urine catecholamine metabolites such as VMA/HVA, and assessment for spread. MIBG imaging is important when the tumor takes up the tracer; alternative imaging is selected for non-avid disease. Marrow sampling is used when indicated. The team also documents tumor biology, including MYCN amplification.

Response is assessed across disease compartments. A shrinking primary mass does not by itself prove that bone or marrow disease has cleared. Keep original images and baseline disease scores so later results can be compared consistently.

The pretreatment INRG staging system separates localized disease without image-defined risk factors (L1) from locoregional disease with one or more such factors (L2). Stage M describes distant spread outside the special MS category. MS applies only to children younger than 18 months with a defined skin, liver and/or limited marrow metastatic pattern; it is not a synonym for all infant metastatic disease.

Risk classification then combines stage with age, histology, MYCN and other biological features, including chromosome findings in the applicable protocol. Revised COG classification incorporates INRG staging and segmental chromosome abnormalities. Ask which cooperative-group system and protocol the team is using; an L2 or M label alone does not define the complete treatment.

Some low-risk tumors are managed with surgery or carefully selected observation. Intermediate-risk treatment may use limited chemotherapy and surgery adjusted to symptoms, biology and response. The aim is adequate disease control with less exposure to late toxicity; removing every visible remnant at the cost of major nerve or vessel injury is not automatically the right goal.

Selected MS tumors can regress, but worsening symptoms, threatening liver enlargement or unfavorable biology can require treatment. Families choosing observation need a written assessment schedule and clear signs for contacting the team.

High-risk care usually starts with induction chemotherapy to reduce disease and allow stem-cell collection and local-control planning. Surgery is coordinated with response and anatomy. Consolidation uses intensive chemotherapy with autologous stem-cell rescue, together with radiotherapy as indicated. Post-consolidation therapy addresses residual disease with anti-GD2-based treatment and differentiation therapy such as isotretinoin.

The randomized COG transplant study found better event-free survival with tandem than single autologous transplantation in its studied strategy. This does not mean any two-transplant program is equivalent: conditioning, prior response and the overall cooperative-group regimen matter. A change between centers should preserve a coherent sequence rather than combine isolated elements from different protocols.

Dinutuximab, dinutuximab beta and naxitamab target GD2 but are not interchangeable labels. US Unituxin is indicated as part of a specified combination after at least a partial response to first-line multimodal treatment in pediatric high-risk disease. European Qarziba includes defined post-induction/transplant and relapsed/refractory settings from age 12 months, with additional conditions for active progression and combination treatment.

US naxitamab with GM-CSF is indicated from age one year for relapsed/refractory high-risk neuroblastoma in bone or marrow after a partial response, minor response or stable disease to prior therapy. It is not a blanket indication for rapidly progressing bulky disease. Anti-GD2 treatment needs experienced monitoring and pain control because infusion reactions, severe pain and neurologic effects can occur.

Eflornithine (Iwilfin, also known as DFMO) is approved in the United States to reduce relapse risk in adults and children with high-risk neuroblastoma who have achieved at least a partial response to prior multimodal treatment including anti-GD2 immunotherapy. The label describes treatment for up to two years unless recurrence or unacceptable toxicity occurs. This is a post-response strategy, not a substitute for induction or treatment of active progression.

Its evidence included comparison with an external control group, rather than a conventional randomized placebo comparison. Hearing, blood counts and liver tests need monitoring; prior platinum-related hearing loss makes this especially relevant. Discuss the expected added benefit, treatment burden and access in the country providing care.

Relapse planning starts with the previous risk group, sites of recurrence, pace, prior response and cumulative toxicity. Refractory disease means an inadequate response to treatment; relapse means disease has returned after control. A new biopsy or molecular profile may reveal a treatment-relevant change. Local relapse and widespread marrow/bone relapse are different problems.

Options can include chemotherapy with an anti-GD2 antibody, an appropriate antibody-based regimen, local control or a trial. The 2026 BEACON Immuno publication evaluated adding dinutuximab beta to temozolomide-based chemotherapy in a randomized phase 2 setting. Its results belong in the evidence discussion, but do not make every anti-GD2/chemotherapy combination equivalent. Naxitamab evidence also comes from a specifically selected bone/marrow population.

Therapeutic iodine-131 MIBG can be considered in selected MIBG-avid relapsed/refractory disease or protocol-defined settings. Diagnostic uptake, marrow reserve, prior radiation and the availability of stem-cell support and radiation-isolation facilities matter. Having had an MIBG scan does not establish suitability for therapeutic MIBG.

For ALK-driven neuroblastoma, lorlatinib has shown activity in early-phase trials and is being studied in the high-risk ANBL1531 program. The relevant finding is an appropriate ALK alteration, not simply a generic positive stain. Early-trial response rates sometimes include minor responses, so they should not be compared uncritically with conventional complete/partial-response rates. Trial use is distinct from a general neuroblastoma marketing approval.

GD2 CAR-T cells are engineered living cells, not an anti-GD2 antibody infusion. The 2025 GD2-CART01 phase 1/2 report described responses and durable remissions in some children with high-risk metastatic, relapsed or refractory neuroblastoma. It was an early-phase, selected population, so the findings do not establish a guaranteed cure or superiority over all other salvage approaches.

Assessment includes disease burden, prior treatments, cell manufacturing and bridging needs, organ function and the study’s specific criteria. Ask the actual trial center about current eligibility and availability. Cytokine-release and neurologic toxicity monitoring remain part of cell-therapy planning; a published trial is not proof that the product is routinely available.

Follow-up covers recurrence and the child’s development. Depending on exposure, late effects can involve hearing, growth, thyroid function, kidneys, heart, fertility, learning and second cancers. Keep a treatment summary with drug totals, transplant conditioning and radiation fields so surveillance follows the actual exposures. Hearing support and school adjustments can matter long before adulthood.

For a specialist review, prepare age at diagnosis, INRG stage and risk assignment, pathology, MYCN and chromosome/molecular reports, MIBG and marrow results, response at each phase, stem-cell collection details and anti-GD2/eflornithine exposure. Ask what problem the proposed next treatment is intended to solve and how it fits the complete pediatric plan.